Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $45.9 million.

  • Editas Medicine's Accumulated Expenses rose 65.09% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 65.09%. This contributed to the annual value of $45.9 million for FY2024, which is 32.68% up from last year.
  • Editas Medicine's Accumulated Expenses amounted to $45.9 million in FY2024, which was up 32.68% from $34.6 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Accumulated Expenses ranged from a high of $45.9 million in FY2024 and a low of $20.2 million during FY2021.
  • In the last 3 years, Editas Medicine's Accumulated Expenses had a median value of $34.6 million in 2023 and averaged $37.2 million.
  • As far as peak fluctuations go, Editas Medicine's Accumulated Expenses declined by 16.03% in 2021, and later skyrocketed by 54.99% in 2022.
  • Yearly analysis of 5 years shows Editas Medicine's Accumulated Expenses stood at $24.0 million in 2020, then fell by 16.03% to $20.2 million in 2021, then soared by 54.99% to $31.3 million in 2022, then increased by 10.44% to $34.6 million in 2023, then spiked by 32.68% to $45.9 million in 2024.